These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16702834

  • 1. Central nervous system infections - a potential complication of systemic immunotherapy.
    Hemmer B, Frohman E, Hartung HP, Stüve O.
    Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834
    [Abstract] [Full Text] [Related]

  • 2. Opportunistic infections and other risks with newer multiple sclerosis therapies.
    Berger JR, Houff S.
    Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
    [Abstract] [Full Text] [Related]

  • 3. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 5. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O.
    J Neurol Sci; 2009 Dec 01; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [Abstract] [Full Text] [Related]

  • 6. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 01; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 7. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F, Stüve O, Weber MS, Zamvil SS, Frohman E.
    Curr Opin Neurol; 2007 Jun 01; 20(3):281-5. PubMed ID: 17495621
    [Abstract] [Full Text] [Related]

  • 8. Future research directions in multiple sclerosis therapies.
    Greenberg BM, Calabresi PA.
    Semin Neurol; 2008 Feb 01; 28(1):121-7. PubMed ID: 18256992
    [Abstract] [Full Text] [Related]

  • 9. Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair.
    Carrithers MD.
    Curr Pharm Biotechnol; 2012 Jun 01; 13(8):1409-17. PubMed ID: 22339217
    [Abstract] [Full Text] [Related]

  • 10. Central Nervous System Infections With Immunomodulatory Therapies.
    Williamson EM, Berger JR.
    Continuum (Minneap Minn); 2015 Dec 01; 21(6 Neuroinfectious Disease):1577-98. PubMed ID: 26633777
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP.
    Nat Clin Pract Neurol; 2006 Apr 01; 2(4):201-11. PubMed ID: 16932551
    [Abstract] [Full Text] [Related]

  • 15. Immunologic aspects of multiple sclerosis.
    Boppana S, Huang H, Ito K, Dhib-Jalbut S.
    Mt Sinai J Med; 2011 Apr 01; 78(2):207-20. PubMed ID: 21425265
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS.
    Adv Neurol; 2006 Apr 01; 98():273-92. PubMed ID: 16400839
    [Abstract] [Full Text] [Related]

  • 20. Immunomodulatory drug treatment in multiple sclerosis.
    Aharoni R.
    Expert Rev Neurother; 2010 Sep 01; 10(9):1423-36. PubMed ID: 20819013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.